These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 3072590)
1. [Possibility of using interferon in the treatment of multiple myeloma]. Piatkowska-Jakubas B; Skotnicki AB; Blicharski J Przegl Lek; 1988; 45(10):747-50. PubMed ID: 3072590 [No Abstract] [Full Text] [Related]
2. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521 [TBL] [Abstract][Full Text] [Related]
3. Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial. Scheithauer W; Cortelezzi A; Fritz E; Kührer I; Polli E; Baldini L; Ludwig H J Biol Response Mod; 1989 Apr; 8(2):109-15. PubMed ID: 2659740 [TBL] [Abstract][Full Text] [Related]
4. [Interferon in the treatment of multiple myeloma]. Kuzmits R; Ludwig H; Cortelezzi A; Van Camp BG; Polli E; Flener R; Scheithauer W Acta Med Austriaca; 1985; 12(5):135-8. PubMed ID: 3914174 [TBL] [Abstract][Full Text] [Related]
5. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)]. Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590 [No Abstract] [Full Text] [Related]
6. [Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone]. Montalbán C; Zapatero A; Blanco L; Sevilla F; García Laraña J; Odriozola J Sangre (Barc); 1984; 29(6):993-9. PubMed ID: 6549486 [No Abstract] [Full Text] [Related]
7. [Polychemotherapy versus melphalan-prednisone in multiple myeloma]. Leoni P; Salvi A; Brianzoni MF; Centurioni R; Montillo M; Olivieri A G Clin Med; 1986 Dec; 67(5-6):291-6. PubMed ID: 3609590 [No Abstract] [Full Text] [Related]
8. [Chemotherapy of multiple myeloma]. Golenkov AK Sov Med; 1991; (3):43-6. PubMed ID: 1882290 [No Abstract] [Full Text] [Related]
9. Interferon in multiple myeloma--does it pay? Kedar I; Segal A Isr J Med Sci; 1995 Oct; 31(10):635-7. PubMed ID: 7591691 [No Abstract] [Full Text] [Related]
10. Rate of M-component changes and clinical course of 23 responsive myeloma patients. Riccardi A; Montecucco C; Merlini G; Cremonini N; Danova M; Ascari E Haematologica; 1984; 69(3):305-14. PubMed ID: 6432642 [No Abstract] [Full Text] [Related]
11. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone. Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265 [No Abstract] [Full Text] [Related]
12. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma]. Le Loët X; Monconduit M; Menard JF; Deshayes P; Grobois B; Tanguy A; Prevost E; Piguet H Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189 [TBL] [Abstract][Full Text] [Related]
13. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039 [TBL] [Abstract][Full Text] [Related]
14. [Preleukemia myelodysplastic syndrome after chemotherapy for multiple myeloma: "a new case"]. Raya Sánchez JM; González Brito G; Marsá Vila L; Brito Barroso ML; Hernández Nieto L Sangre (Barc); 1991 Oct; 36(5):434-5. PubMed ID: 1816642 [No Abstract] [Full Text] [Related]
15. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness. Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662 [TBL] [Abstract][Full Text] [Related]
16. [Combination chemotherapy with melphalan, cyclophosphamide, vincristine, ACNU and prednisolone (MEV(Ac)P) for multiple myeloma]. Takagi T; Oguro M; Sakai C Rinsho Ketsueki; 1986 Dec; 27(12):2249-53. PubMed ID: 3471977 [No Abstract] [Full Text] [Related]
17. [Combined treatment, polychemotherapy and amino-hydroxybutylidene-diphosphonate, of a patient with multiple myeloma: remission and long survival]. Attardo-Parrinello G; Merlini G; Crema F; Fiorentini ML; Mazzone A; Cotti-Piccinelli E Medicina (Firenze); 1988; 8(3):318-20. PubMed ID: 3231044 [No Abstract] [Full Text] [Related]
18. [Rheumatoid arthritis and multiple myeloma--the risk of a combination of the 2 diseases]. Lila AM; Mazurov VI; Novik AA Ter Arkh; 1997; 69(2):50-2. PubMed ID: 9173578 [No Abstract] [Full Text] [Related]
19. Refractory multiple myeloma treated with homoharringtonine: report of two cases. Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891 [No Abstract] [Full Text] [Related]
20. [Pneumonia caused by Salmonella in a patient with myeloma]. Fernández P; Roldán V; García MC; Gil MT; Rivas C Sangre (Barc); 1995 Jun; 40(3):234-5. PubMed ID: 7570286 [No Abstract] [Full Text] [Related] [Next] [New Search]